Immix Biopharma, Inc. (IMMX) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
The consensus price target is $13.00 (low: $12.00, high: $14.00), representing an upside of 32% from the current price $9.85.
Analysts estimate Earnings Per Share (EPS) of $-0.80 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.76 vs est $-0.80 (beat +4.4%). 2025: actual $-0.89 vs est $-0.66 (missed -34.2%). Analyst accuracy: 85%.
IMMX Stock — 12-Month Price Forecast
$13.00
▲ +31.98% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Immix Biopharma, Inc., the average price target is $13.00, with a high forecast of $14.00, and a low forecast of $12.00.
The average price target represents a +31.98% change from the last price of $9.85.
Highest Price Target
$14.00
Average Price Target
$13.00
Lowest Price Target
$12.00
IMMX Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Immix Biopharma, Inc. in the past 3 months
EPS Estimates — IMMX
85%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.76
vs Est –$0.80
▲ 4.6% off
2025
Actual –$0.89
vs Est –$0.66
▼ 25.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — IMMX
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
